Pharmaceutical industry
Scientists at InNexus Biotechnology have designed a novel antibody product, IXSCD11a, aimed at treating psoriasis, an autoimmune skin disease, using the company's proprietary dermal permeating Transmab technology. The product is being formulated for topical use and has shown significant increase in cell penetration compared to other products targeting
Pharmaceutical industry
Pfizer and Debiopharm have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. The partnership aims to leverage the combined expertise of both companies in developing a personalized
Drugs
Continuous treatment with the oral drug REVLIMID following a stem cell transplant significantly prolongs remission in patients with multiple myeloma, according to a new study sponsored by the National Cancer Institute. This approach allows patients to manage their cancer while living an active lifestyle, as demonstrated by Elijah Alexander, founder
Drugs
Cancer patients may benefit from a novel carbohydrate polymer developed by Pro-Pharmaceuticals, Inc. DAVANAT targets Galectin receptors over-expressed on cancer cells, potentially increasing survival rates and reducing side effects. Preliminary results from clinical trials suggest that combining DAVANAT with chemotherapy or biologics can extend median survival and decrease adverse reactions.
Drugs
YM BioSciences, a Canadian biopharmaceutical company, has announced that it has signed an agreement with Therapure Biopharma to provide fill and finish services for its humanized monoclonal antibody, nimotuzumab. The agreement will enable YM BioSciences to leverage Therapure's aseptic GMP certified and Health Canada-licensed fill suite in Mississauga,
Drugs
Cubist Pharmaceuticals, a leading acute care therapeutics company, has announced the signing of a definitive agreement to acquire Calixa Therapeutics Inc., a biopharmaceutical company focused on developing novel antibiotics to address the expanding problem of multi-drug resistant Gram-negative pathogens. The acquisition is expected to close in the fourth quarter of
Drugs
Genentech, Inc., a wholly owned member of the Roche Group, has announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1) in women with advanced HER2-positive breast cancer. The study, known as TDM4374g, found that T-DM1 shrank tumors in 33 percent of women with metastatic HER2-positive breast cancer that
Drugs
Researchers at Kanazawa University have identified a previously unknown mechanism through which advanced prostate cancer (PCa) often relapses after androgen deprivation therapy (ADT). The study, published in Endocrine-related Cancer, reveals that prostate stromal cells and androgen-sensitive PCa LNCaP cells coordinately activate the androgen receptor through the synthesis of testosterone and
Drugs
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center regarding an immunotherapy targeting cancer stem cells (CSCs). This new therapy has shown significant promise in pre-clinical animal models, targeting and destroying CSCs. The agreement bolsters ImmunoCellular's
Drugs
Researchers at the University of Illinois have conducted several studies on lunasin, a soy peptide often discarded in waste streams, and found promising results in its ability to fight leukemia, block inflammation, and provide benefits against chronic health conditions such as diabetes, heart disease, and stroke. The studies suggest that
Drugs
Scientists in the United States have reported the development of a novel cationic polymer, EGDE-3,3', that significantly enhances adenoviral gene therapy for cancer. The polymer was found to increase infectivity and transgene expression, with a 100-fold reduction in the amount of adenovirus required to transduce 50-60% of cancer
Drugs
Researchers at Uppsala University in Sweden have been investigating the potential of CD40 ligand (CD40L) gene therapy in treating aggressive bladder cancer. Their study, published in the Journal of Immunotherapy, involved using adenoviral vectors to deliver the CD40L gene into the bladder of mice with disseminated cancer. The results showed
